Biocon Limited has informed the Exchange regarding a press release dated August 07, 2025, titled "Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%EBITDA at Rs 829 Cr; Up 19%*;PBT (before exceptional item) at Rs 97 Cr, Up 72%*Biosimilars Up 18%, CRDMO Up 11% and Generics Up 6%".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon reported Q1FY26 (quarter ended June 30, 2025) consolidated operating revenue of Rs 3,942 crore, up 15% year-on-year on a like-for-like basis. Total revenue came in at Rs 4,022 crore. EBITDA rose 19% (like-for-like) to Rs 829 crore with a 21% margin, while core EBITDA grew 11% to Rs 1,003 crore at a 25% margin. Profit before tax (before exceptional items) stood at Rs 97 crore, up 72% on a like-for-like basis, and reported net profit was Rs 31 crore. The Biosimilars segment (Biocon Biologics) led growth at Rs 2,458 crore (+18%), followed by CRDMO/Syngene at Rs 875 crore (+11%) and Generics at Rs 697 crore (+6%). Key highlights included the launch of Yesafili in Canada (10th biosimilar), USFDA approval for Kirsty (Insulin Aspart), and a successful Rs 4,500 crore QIP fundraise in June 2025 to increase Biocon's stake in Biocon Biologics. Note: Q1FY25 included a one-time Rs 1,057 crore gain from the BFI divestment, which inflates the YoY drop in reported total revenue (-12%) and EBITDA (-53%).
The underlying business is clearly growing — Biosimilars momentum and new product approvals (Insulin Aspart, Denosumab biosimilars) strengthen the long-term story, while the Rs 4,500 crore QIP boosts the balance sheet and simplifies Biocon Biologics' ownership. Reported net profit and EBITDA still look weak on a head-to-head YoY basis because of last year's one-time gain, so investors should focus on like-for-like figures and segment-level trends rather than the headline comparisons.